LONG-TERM FUNCTIONAL IMPROVEMENTS IN THE 2-YEAR TREATMENT OF SCHIZOPHRENIA OUTPATIENTS WITH OLANZAPINE LONG-ACTING INJECTION

被引：0
|
作者：
Ascher-Svanum, Haya [1 ]
Novick, Diego [2 ]
Haro, Josep M. [3 ]
Bertsch, Jordan [3 ]
McDonnell, David [1 ]
Detke, Holland [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Windlesham, Surrey, England
[3] Univ Barcelona, CIBERSAM, Parc Sanitari St Joan Deu, Barcelona, Spain
来源：
SCHIZOPHRENIA RESEARCH | 2012年 / 136卷
关键词：
D O I：
10.1016/S0920-9964(12)70521-2
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
207
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [31] One-year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting intramuscular risperidone
    Chue, P
    Devos, E
    Duchesne, I
    Leal, A
    Mehnert, A
    [J]. SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 277 - 278
  • [32] Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
    Heres, Stephan
    Kraemer, Susanne
    Bergstrom, Richard F.
    Detke, Holland C.
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (06) : 299 - 312
  • [33] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison
    Dilla, Tatiana
    Moeller, Joergen
    O'Donohoe, Paul
    Alvarez, Maria
    Sacristan, Jose A.
    Happich, Michael
    Tockhorn, Antje
    [J]. BMC PSYCHIATRY, 2014, 14
  • [34] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
    Tatiana Dilla
    Jörgen Möller
    Paul O’Donohoe
    María Álvarez
    José A Sacristán
    Michael Happich
    Antje Tockhorn
    [J]. BMC Psychiatry, 14
  • [35] COST-EFFECTIVENESS OF LONG-ACTING OLANZAPINE VERSUS LONG-ACTING RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA IN SPAIN
    Dilla, T.
    O'Donohoe, P.
    Moeller, J.
    Alvarez, M.
    Sacristan, J.
    San, L.
    Happich, M.
    Tockhorn, A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A292 - A292
  • [36] Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
    Ascher-Svanum, Haya
    Montgomery, William S.
    McDonnell, David P.
    Coleman, Kristina A.
    Feldman, Peter D.
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2012, 5 : 391 - 398
  • [37] LONG-TERM TREATMENT OF ACROMEGALY WITH A LONG-ACTING ANALOG OF SOMATOSTATIN
    CHNG, LJC
    SANDLER, LM
    KRAENZLIN, ME
    BURRIN, JM
    JOPLIN, GF
    BLOOM, SR
    [J]. BRITISH MEDICAL JOURNAL, 1985, 290 (6464): : 284 - 285
  • [38] Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine
    McDonnell, David P.
    Kryzhanovskaya, Ludmila A.
    Zhao, Fangyi
    Detke, Holland C.
    Feldman, Peter D.
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (06) : 422 - 433
  • [39] Cognitive and functional improvement with long term treatment with long-acting risperidone
    Harvey, PD
    Pandina, G
    Bilder, RM
    Rodriguez, S
    Turkoz, I
    Gharabawai, G
    [J]. NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S129 - S129
  • [40] OVERCOMING THE CHALLENGES OF MODELLING SCHIZOPHRENIA: A UK CASE STUDY OF THE COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION VS. RISPERIDONE LONG-ACTING INJECTION
    Carroll, S. M.
    Jemiai, N.
    Moller, J.
    Novick, D.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A350 - A350
12345